Phase 3 Alzheimer's Disease Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have a confirmed diagnosis of Alzheimer's disease at the mild or moderate stage, confirmed using specific updated diagnostic guidelines from 2024.
• People who score between 12 and 22 (inclusive) on a standard memory and thinking test called the MMSE, taken at the screening appointment.
• People who have a designated caregiver who spends around 10 or more hours per week with them, is willing to attend all study visits, helps oversee medication, and agrees to take part in study-related activities themselves.
• People who are taking Alzheimer's medications called AChEIs and/or memantine must have been on a stable dose for at least 12 weeks before screening, and the dose must remain stable throughout the study.

Who may not be able to join:

• People who have significant or serious medical conditions that could affect their safety or the study results — including any level of liver problems, difficulty emptying the bladder, active gallbladder disease, moderate-to-severe kidney problems, or unstable high blood pressure or fast heart rate.
• People who have a primary psychiatric diagnosis such as major depression, schizoaffective disorder, or bipolar disorder, or who have severe psychiatric symptoms that could affect how the study results are interpreted.
• People who have a history of schizophrenia or long-term psychosis, have previously taken the study drug KarXT, or have received Alzheimer's disease-modifying anti-amyloid treatments within the past 6 months before screening.
• People whose brain MRI scan at screening shows significant abnormal findings that could affect safety or interfere with the study.
• There may be additional criteria not listed here (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.